TRPC6 and focal segmental glomerulosclerosis: AC-1903, which inhibits TRPC5 less potently (IC50 = 14.7 μM) but does not inhibit TRPC4 or TRPC6 channels, was also effective in the transgenic rat model mentioned above and in a model of hypertension-induced FSGS (Dahl salt-sensitive rats), reducing proteinuria and protecting podocytes.201